22 August 2025 Sydney, Australia

Full Year Results FY2025

Highlights:

- Demonstrated statistically significant neuroprotection in traumatic brain injury (TBI) preclinical model.
- Demonstrated statistically significant cardioprotection in mitigating myocardial ischemia reperfusion injury, including reduced incidence of life-threatening arrhythmias.
- Composition of matter patent application submitted with an international patent search confirming novelty and inventiveness.
- Research and development costs of $4.38M (FY2024: $2.03M), approximately 59 percent of expenditure.
- Accrued (estimated) R&D rebate of $2.16M expected to be received in the quarter ending 31 December 2025.
- Cash at bank $2.93M (FY20234: $4.77M).

Subsequent to year end:

- Successful completion of Phase I clinical trial to assess safety, tolerability, and pharmacokinetics of Nyrada's lead drug candidate Xolatryp™.
- Planning underway for Phase IIa clinical trial to assess safety and explore efficacy of Xolatryp in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing Percutaneous Coronary Intervention (PCI).
- $8.25 million of new equity capital raised (before costs).

Nyrada Inc (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today released its 2025 financial year audited accounts and Annual Report.

Over the course of FY2025, Nyrada remained firmly focused on its mission to develop next-generation small-molecule therapies targeting Transient Receptor Potential Canonical (TRPC) ion channels. At the centre of this mission was the continued advancement of the Company's lead drug candidate, Xolatryp™ (formerly known as NYR-BI03), which achieved significant progress across both clinical and preclinical programs, signalling a pivotal chapter in Nyrada's growth.

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

Nyrada CEO James Bonnar commented: "The 2025 financial year has been another transformative year for Nyrada, with a strengthened intellectual property position, a solid financial foundation, and strong clinical momentum. We are well positioned to deliver on our mission of developing breakthrough therapies targeting TRPC ion channels. FY2026 promises to be another pivotal year for Nyrada.

"Notably, during the year, we initiated our first-in-human Phase I trial of Xolatryp. This trial was successfully completed soon after the conclusion of the financial year, permitting us to progress towards a Phase IIa clinical trial in acute myocardial infarction."

Clinical Development

A major milestone was reached during the year with the commencement of Nyrada's first-in-human Phase I clinical trial of Xolatryp. Conducted at Scientia Clinical Research with the support of Southern Star Research, the study was designed to evaluate the safety, tolerability, and pharmacokinetics of Xolatryp in healthy human volunteers.

By 30 June 2025, four of six planned cohorts had been completed, with the fifth and sixth reporting shortly after year-end. The trial concluded without any dose-limiting toxicities, unexpected adverse events, or safety concerns identified.

Preclinical Advancements

Progress in pre-clinical research further reinforced the therapeutic potential of Xolatryp. In April 2025, Nyrada reported results from a collaborative study with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney, which demonstrated statistically significant neuroprotection in a rodent model of penetrating traumatic brain injury (TBI). These results build on earlier stroke studies where Xolatryp preserved brain tissue in the penumbra region of the brain.

In addition, Xolatryp demonstrated compelling cardioprotective effects. In October 2024, Nyrada announced pre-clinical results showing an 86 percent cardioprotective benefit following myocardial ischemia reperfusion injury, with echocardiography confirming marked structural and functional improvements. A follow-up study in May 2025 demonstrated a 42 percent cardioprotective effect with a shorter duration infusion, alongside reduced biomarkers of cardiac injury and a significant lowering of life-threatening arrhythmias such as ventricular fibrillation and tachycardia.

Collectively, these outcomes highlight Xolatryp as a versatile, first-in-class therapeutic with potential applications in conditions where no FDA-approved treatments currently exist.

Corporate and Other Activities

During the 2025 financial year, the Company successfully raised $3.45 million (before costs) via a fully subscribed placement and Securities Purchase Plan. Additional participation from Non-Executive Directors was secured following approval at the Extraordinary General Meeting held in April 2025.

Subsequent to the conclusion of the financial year, an additional $8.25 million (before costs) was raised by way of a placement from new and existing professional and sophisticated investors, and Non-Executive Directors.

Nyrada continues to be disciplined in its capital allocation decisions including maintaining a lean operating model with the majority of resources allocated towards research and development. In the 2025 financial year, approximately 59 percent of expenditure was on research and development ($4.38 million).

Consistent with prior years, Nyrada intends to lodge a claim under the Commonwealth Government's Research and Development Tax Incentive scheme for research conducted in the 2025 financial year, with an expected refund of $2.16 million to be received in the quarter ending 31 December 2025.

Outlook

As Nyrada enters the 2026 financial year, it does so with strong clinical momentum, compelling scientific validation, and a clear roadmap toward initiating a Phase IIa trial of Xolatryp. With the final Phase I study report imminent and additional indications under evaluation, the Company is well-positioned to unlock further value for shareholders as it advances the development of Xolatryp.

- ENDs -

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.